Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results